PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-nave subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).